GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » Probability of Financial Distress (%)

LGVN (Longeveron) Probability of Financial Distress (%) : 0.42% (As of Jan. 19, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Longeveron Probability of Financial Distress (%)?

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Longeveron's Probability of Financial Distress (%) is 0.42%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Competitive Comparison of Longeveron's Probability of Financial Distress (%)

For the Biotechnology subindustry, Longeveron's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longeveron's Probability of Financial Distress (%) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longeveron's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Longeveron's Probability of Financial Distress (%) falls into.



Longeveron Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-5.48

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=0.42%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).


Longeveron  (NAS:LGVN) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Longeveron Probability of Financial Distress (%) Related Terms

Thank you for viewing the detailed overview of Longeveron's Probability of Financial Distress (%) provided by GuruFocus.com. Please click on the following links to see related term pages.


Longeveron Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » Probability of Financial Distress (%)
Traded in Other Exchanges
N/A
Address
1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
Executives
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Hashad Mohamed Wa'el Ahmed officer: Chief Executive Officer SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136
Joshua Hare director, officer: Chief Scientific Officer C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073
Rock Soffer director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Cathy Ross director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Jeffrey Pfeffer director
Lisa Locklear officer: Chief Financial Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Nataliya Agafonova officer: Chief Medical Officer 1951 NW 7TH AVENUE, MIAMI FL 33136
James Clavijo officer: CFO and Treasurer 1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139
Kwan-hong Christopher Min officer: Chief Medical Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Todd C Girolamo director 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Geoff Green officer: CEO 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Paul T Lehr officer: General Counsel, Secretary 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Ursula Ungaro director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Donald M Soffer director, 10 percent owner 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136